ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2966

Pulmonary Involvement in Systemic Sclerosis at Initial Presentation: A Single Center Experience

Ranadeep Mandhadi1 and Santhanam Lakshminarayanan2, 1Division of Rheumatology, The University of Connecticut Health Center, Farmington, CT, 2Division of Rheumatology, University of Connecticut Health Center, Farmington, CT

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: interstitial lung disease and scleroderma

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Systemic Sclerosis (SSc) is a rare heterogeneous autoimmune connective tissue disease.Pulmonary involvement is the major cause of mortality and morbidity in Systemic sclerosis. The aim of the study is to provide a single center experience of SSc patients diagnosed at a tertiary care center over a continuous period of 10 years, in regards to the extent and characteristics of interstitial lung disease at the time of initial presentation

Methods:

Retrospectively reviewed the charts of all the SSc patients who presented to The University of Connecticut Health Center Rheumatology clinic for the first time from April,2004 to March, 2014. All patients fulfilled the 2013 ACR/EULAR classification criteria for SSc, applied retrospectively at the time of chart review. Information about patient’s demographics, laboratory, imaging studies and procedures including chest x- ray (CXR), high resolution CT (HRCT) of lung , pulmonary function tests ( PFT’s) and esophageal transit time (ETT) done at the time of their initial presentation were collected

Results:

128 patients were identified with either limited cutaneous (111) or diffuse cutaneous (17) variant SSC, of whom 120 (94%) were female and 95 (74%) were white. SCL-70 was positive in 18% and anti-centromere antibody was positive in 32% of patient’s. Complete report of the PFT’s was available in 104 patients. FVC was less than 70% in 20 (19%) patients. Of these, 4 had normal HRCT of the lung and 16 patients had interstitial changes. DLCO was less than 70% in 16 of the 20 patients with abnormal FVC. Of the remaining 84 patients with normal FVC, 10 (12%) patients had abnormal CXR and of the 62 patients with both normal FVC and normal CXR, 15 (24%) patients had an abnormal HRCT.

 Among the 122 patients who had HRCT lung, 52 (43%) had abnormal HRCT including the 18 patients with only minimal ground glass changes and 34 patients with honeycombing and or fibrosis mostly limited to the subpleural space . Among the 52 patients with abnormal HRCT 28 (54%) patients had either an abnormal CXR or FVC. The remaining 24 patients with an abnormal HRCT had a normal FVC and CXR which accounts for 20% of total patients.

Of the 52 patients with abnormal HRCT lung, ETT was normal in 16 (30%) patients and abnormal in 35 (67%) patients.  Of the 70 patients with normal HRCT, ETT was normal in 31(44%) patients and abnormal in 36 (51%) patients. No statistically significant difference was seen in the incidence of ETT in people with and without HRCT lung abnormalities (2 tailed p value was 0.129 using Fisher’s exact test)

Conclusion:

Majority of patients presenting to University of Connecticut Health Center had limited cutaneous variant of SSc .Interstitial lung disease as diagnosed with HRCT lung was seen in more than 40% of patients with Systemic Sclerosis at the time of diagnosis. More than one third of these patients had only minimal ground glass opacities. Even though HRCT lung was abnormal in one fourth of the patients with normal FVC and chest x-ray, none of the patients had ILD severe enough to require treatment. Esophageal dysmotility is seen more often in patients with HRCT lung abnormalities but it was not statistically significant.


Disclosure: R. Mandhadi, None; S. Lakshminarayanan, None.

To cite this abstract in AMA style:

Mandhadi R, Lakshminarayanan S. Pulmonary Involvement in Systemic Sclerosis at Initial Presentation: A Single Center Experience [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/pulmonary-involvement-in-systemic-sclerosis-at-initial-presentation-a-single-center-experience/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pulmonary-involvement-in-systemic-sclerosis-at-initial-presentation-a-single-center-experience/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology